Commission channels funds into health tech research and innovation under FP7
This article was originally published in Clinica
The European Commission is allocating Euro7.3bn ($8.8bn) to the "specific programme" for health under the Seventh Framework Programme for Research and Development (FP7). Emphasis will be put on "transitional research", turning basic discoveries into clinical application, as well as on supporting the development of:
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.